LENSAR Q2 revenue rises 18%, returns to profit

LENSAR

13/08/2026 12:17

Overview
US robotic cataract laser maker's Q2 revenue grew 18% yr/yr, recurring revenue up 20%
Net income turned positive, aided by improved revenue and lower operating expenses
Company's ALLY system placements and backlog increased, reflecting sustained demand

Outlook
Company did not provide specific financial guidance for future quarters or the full year

Result Drivers
ALLY SYSTEM DEMAND - Co said sustained demand for ALLY robotic cataract laser systems drove growth in placements and backlog
PROCEDURE REVENUE GROWTH - Co said procedure revenue grew 23% yr/yr as surgeons increased use of ALLY systems
LOWER OPERATING EXPENSES - Net income and Adjusted EBITDA increased due to improved revenue, lower operating expenses, and a $1.1 million tariff refund

Company press release: ID:nGNX34zWPh

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$16.50 mln
$14.65 mln (2 Analysts)
Q2 EPS
 
$0.10
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for LENSAR Inc is $8.50, about 35.1% above its August 12 closing price of $6.29

Reuters Recommended Reads
Aug 11 - Eye care company Alcon raises margin outlook, shares jump
Aug 11 - LENZ Therapeutics Q2 revenue rises on VIZZ sales
Aug 12 - STAAR Surgical Q2 net sales jump on China sales growth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)